Re-Stem Biotech Signs Research Agreement with America's First Research University to Study Progression of Parkinson's Disease

The Research Will Also Study Related Neurodegenerative Diseases

SUZHOU, China - June 28, 2019 - PRLog -- Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, spinal cord injury and cancer, today announced the signing of a sponsored research agreement with the first research university in the United States, ranked among the top five universities in the world, in order to conduct an academic research study entitled Molecular Pathways that Modulate the Mitochondria-Proteostasis Relationship during the Progression of Parkinson's Disease and related neurodegenerative diseases.

"We are very pleased to partner with a highly respected institution in our efforts to address degenerative conditions," commented Benno Jiao, CEO of the Company. "A treatment that could slow or stop Parkinson's progression would have a large impact on the quality of life to the millions of patients worldwide living with this disease and the many more who will become at risk as populations age."

The focus of the research will be to study molecular pathways that modulate the mitochondria-proteostasis relationship during the progression of Parkinson's disease (PD) using cell-based experimental models and mice. These pathways may be targeted for better maintenance of proteostasis and mitochondrial fitness. The goal of the study is to support the research and development of new therapeutics for delaying brain aging and the progression of PD and possibly other neurodegenerative diseases.

About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing, Kunming and Ganzhou.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as "will," "may," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.

Contact
Judyanna Chen
Re-Stem Biotech
***@restembiotech.com
Photos: (Click photo to enlarge)



Read Full Story - Re-Stem Biotech Signs Research Agreement with America's First Research University to Study Progression of Parkinson's Disease | More news from this source

Press release distribution by PRLog